Join the club for FREE to access the whole archive and other member benefits.

UNITY Biotechnology

Biotechnology company devoted to research of restoring human health

UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.

Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.

Visit website: https://unitybiotechnology.com/

 unity-biotechnology

 UnityBiotech

People at UNITY Biotechnology

Nathaniel David

Co-Founder and President, Unity Biotechnology

Anirvan Ghosh

Chief Executive Officer at UNITY Biotechnology.

Keith Leonard

Chairman and CEO of UNITY Biotechnology.

Jamie Dananberg

Chief Medical Officer at Unity Biotechnology.

UNITY Biotechnology News

UNITY Biotech's lead compound lags behind the Regeneron’s eye drug

Biospace - 27-May-2023

UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required

Read more...

Unity Biotechnology's diabetic macular edema senolytic treatment shows promise at 48-week endpoint

FierceBiotech - 24-Apr-2023

Corporate shift towards ophthalmology puts senolytics head-to-head against existing treatments

Read more...

Data from Phase 2 BEHOLD study of UBX1325 in DME patients-Unity Biotechnology

Ophthalmology Times - 12-Aug-2022

Statistically significant treatment effect for both BCVA and CST was seen at both 12 and 18 weeks

Read more...

Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021

Longevity Technology - 25-Feb-2022

Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.

Read more...

Longevity Technology interviews Aubrey de Grey about senolytics and other senotherapeutics

Longevity Technology - 05-Aug-2021

Most approaches have their limitations but good progress is being made on several fronts

Read more...

Unity's senolytic drug reports positive phase 1 data in eye disease patients

FierceBiotech - 06-Jul-2021

Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness

Read more...

Super summary of 3rd Annual Longevity Therapeutics Summit

Lifespan.io (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Read more...

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Read more...

Unity Biotechnology launches clinical trial of a new senolytic

Lifespan.io (LEAF) - 13-Oct-2020

A new approach to treat diabetic macular oedema

Read more...

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed

Read more...

Reason examines the failure of Unity Biotechnology's phase 2 senolytics trial

Fight Aging! - 18-Aug-2020

Disappointing first result - but lessons learnt and plenty of other strategies available

Read more...

Research into klotho is at a very interesting point

Fight Aging! - 03-Jun-2019

Research community is littered with interesting, promising foundations for therapies to treat aging

Read more...

UNITY Biotechnology expands trial of osteoarthritis senolytic

UNITY Biotechnology - 22-Jan-2019

Initial results must be promising to enrol more patients at highest dosage

Read more...

UNITY Biotechnologies Selects a New Senolytic Candidate

Lifespan.io (LEAF) - 14-Jan-2019

Very early days but good to have more senolytics in the pipeline

Read more...

The path to an extended health span and a healthier death

MIT Technology Review - 23-Oct-2018

Still a long way to go before expanding life span

Read more...

Cleara Biotech Joins the Race to Develop Senolytic Therapies

Lifespan.io (LEAF) - 09-Jul-2018

This therapy uses a modified FOXO4 to promote apoptosis in senescent cells

Read more...

Silicon Valley and rich people invest to slow down ageing and live longer

This Is Money - 17-Mar-2018

All the money in the world to fight ageing and death

Read more...

SRF has made progress in the fight against ageing

Lifespan.io (LEAF) - 05-Dec-2017

R&D phase in SENS repair approach has shown promising results

Read more...

Here are the ways Silicon Valley plans to conquer death

National Post - 03-Nov-2017

Billionaires are now pouring millions into longevity research. Upgrading the human immune system...

Read more...

To stay young, kill zombie cells

Nature - 24-Oct-2017

Proof-of-concept trials starting that pit senolytic drugs against a range of age-related ailments...

Read more...

Display all news